2025 third_quarter Filing

Issues related to domestic healthcare and pricing; Issues related to cell, gene therapies, and radioligand therapies; Issues related to supply chain management, issues related to intellectual property; and issues related to tariffs.

Issues related to ongoing trade negotiations; Issues related to US/China relations; Issues related to international intellectual property; Issues related to global health; issues related to supply chain; and issues related to tariffs.